Advertisement
Canada markets close in 1 hour 34 minutes

  • S&P/TSX

    22,037.81
    +165.85 (+0.76%)
     

  • S&P 500

    5,075.66
    +65.06 (+1.30%)
     

  • DOW

    38,533.00
    +293.02 (+0.77%)
     

  • CAD/USD

    0.7321
    +0.0020 (+0.27%)
     

  • CRUDE OIL

    83.35
    +1.45 (+1.77%)
     

  • Bitcoin CAD

    91,285.09
    +319.07 (+0.35%)
     

  • CMC Crypto 200

    1,437.04
    +22.28 (+1.57%)
     

  • GOLD FUTURES

    2,342.10
    -4.30 (-0.18%)
     

  • RUSSELL 2000

    2,008.29
    +40.81 (+2.07%)
     

  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     

  • NASDAQ

    15,725.00
    +273.70 (+1.77%)
     

  • VOLATILITY

    15.93
    -1.01 (-5.96%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Stocks in play: Trillium Therapeutics Inc.

Baystreet.ca
Updated
Reported financial and operating results for the year ended December 31, 2017. As of December 31, 2017, ...

Reported financial and operating results for the year ended December 31, 2017. As of December 31, 2017, Trillium had cash and cash equivalents and marketable securities, and working capital of $81.8 million and $68.9 million, respectively, compared to $50.5 million and $45.5 million, respectively at December 31, 2016. Net loss for the year ended December 31, 2017 of $45.1 million was higher than the loss of $31.7 million for the year ended December 31, 2016. Trillium Therapeutics Inc.